Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Short term Debt (2017 - 2025)

Bioceres Crop Solutions' Short term Debt history spans 9 years, with the latest figure at $119.7 million for Q2 2025.

  • On a quarterly basis, Short term Debt fell 12.45% to $119.7 million in Q2 2025 year-over-year; TTM through Jun 2025 was $119.7 million, a 12.45% decrease, with the full-year FY2025 number at $119.7 million, down 12.45% from a year prior.
  • Short term Debt hit $119.7 million in Q2 2025 for Bioceres Crop Solutions, down from $136.7 million in the prior quarter.
  • Over the last five years, Short term Debt for BIOX hit a ceiling of $136.7 million in Q2 2024 and a floor of $5.7 million in Q2 2021.
  • Historically, Short term Debt has averaged $77.7 million across 5 years, with a median of $76.8 million in 2021.
  • Biggest five-year swings in Short term Debt: skyrocketed 50.96% in 2023 and later decreased 12.45% in 2025.
  • Tracing BIOX's Short term Debt over 5 years: stood at $25.9 million in 2021, then surged by 175.2% to $71.3 million in 2022, then surged by 50.96% to $107.6 million in 2023, then rose by 27.04% to $136.7 million in 2024, then dropped by 12.45% to $119.7 million in 2025.
  • Business Quant data shows Short term Debt for BIOX at $119.7 million in Q2 2025, $136.7 million in Q2 2024, and $107.6 million in Q2 2023.